Adjuvant Short-Course Trastuzumab in Breast Cancer

Autor: Geetha Senguttuvan, Shirley Sundersingh, Manikandan Dhanushkodi, Trivadi S. Ganesan, Archit Joshi, Hemanth Raj, Selvaluxmy Ganesarajah, Arun Kumar Rajan, Priya Iyer, Nikita Mehra, Gangothri Selvarajan, Sridevi Velusamy, Taha Sethjiwala, Jayachandran Perumal Kalaiarasi, Venkatraman Radhakrishnan, Arvind Krishnamurthy, Tenali Gnana Sagar, Rama Ranganathan, Bharathi Srilatha, Balasubramanian Ananthi
Rok vydání: 2019
Předmět:
Zdroj: Indian Journal of Gynecologic Oncology. 17
ISSN: 2363-8400
2363-8397
Popis: The standard duration of adjuvant trastuzumab is 1 year. But the decision to use for 1 year was chosen arbitrarily in clinical trials. Many patients from developing countries like India cannot afford 1 year of adjuvant trastuzumab. We retrospectively analysed 70 patients with HER2-positive breast cancer, who received short-course trastuzumab, and compared them with a matched historical cohort (n = 65) of HER2-positive breast cancer patients who did not receive trastuzumab. The 1-year DFS and OS of patients who received short-course trastuzumab were 91% and 96%, respectively. This cohort was matched for age, stage and menopausal status with a historical cohort (N = 65) of HER2-positive breast cancer who did not receive trastuzumab. The 1-year DFS (94 vs 71%, p = 0.045) and 1-year OS (94 vs 80%, p = 0.006) were superior for those who received short-course trastuzumab. Adjuvant short-course trastuzumab (weekly for 9 weeks) improved survival in HER2-positive breast cancer as compared to the historical cohort without trastuzumab.
Databáze: OpenAIRE
Externí odkaz: